Pitfalls of diagnosis based on abnormal flow cytometry and [ 18F]fluorodeoxyglucose positron emission tomography

Clinical Lymphoma and Myeloma

Volumn 8, Issue 2, 2008, Pages 117-120

  Bhargava, Parul ^a   Anthony Parker, J ^a   Dezube, Bruce J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

CD10; CD5; Fine needle aspirate biopsy; Follicular hyperplasia

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FLUORODEOXYGLUCOSE F 18; RITUXIMAB;

ADULT; ARTICLE; ASPIRATION BIOPSY; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER GRADING; CANCER RELAPSE; CASE REPORT; CELL POPULATION; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; CYTOLOGY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; GERMINAL CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPH NODE; LYMPHOCYTE; LYMPHOID CELL; MACROPHAGE; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE C MYC; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 44649116490     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.014     Document Type: Article

References (14)

1. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106:1376-81.
2. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-9.
3. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16:1514-23.
4. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14:123-30.
5. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. Aids 2006; 20:985-93.
6. Shapiro AL, Pincus RL. Fine-needle aspiration of diffuse cervical lymph-adenopathy in patients with acquired immunodeficiency syndrome. Otolaryngol Head Neck Surg 1991; 105:419-21.
7. Burton F, Patete ML, Goodwin WJ, Jr. Indications for open cervical node biopsy in HIV-positive patients. Otolaryngol Head Neck Surg 1992; 107:367-9.
8. Moresco L, Gipponi M, CaFiero F, et al. Role of diagnostic lymphnode biopsies in 56 anti-HIV positive patients. Cancer Detect Prev 1990; 14:353-7.
9. Bottles K, McPhaul LW, Volberding P. Fine-needle aspiration biopsy of patients with acquired immunodeficiency syndrome (AIDS): experience in an outpatient clinic. Ann Intern Med 1988; 108:42-5.
10. Strigle SM, Martin SE, Levine AM, et al. The use of fine needle aspiration cytology in the management of human immunodeficiency virus-related non-Hodgkin's lymphoma and Hodgkin's disease. J Acquir Immune Defic Syndr 1993; 6:1329-34.
11. Reid AJ, Miller RF, Kocjan GI. Diagnostic utility of fine needle aspiration (FNA) cytology in HIV-infected patients with lymphadenopathy. Cytopathology 1998; 9:230-9.
12. Matsubayashi S, Tamai H, Morita T, et al. Hashimoto's thyroiditis manifesting monoclonal lymphocytic infiltration. Clin Exp Immunol 1990; 79:170-4.
13. Jorgensen JL. State of the Art Symposium: flow cytometry in the diagnosis of lymphoproliferative disorders by fine-needle aspiration. Cancer 2005; 105:443-51.
14. Kussick SJ, Kalnoski M, Braziel RM, et al. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol 2004; 121:464-72.